Patents covering the core technology have now been released in Canada.

Canadian Intellectual Property Office grants patent to CardioGenics’ QL Care Analyzer CardioGenics Holdings Inc. Patents covering the ‘core technology’ have now been released in Canada, the European Japan and Union viagra-vs-cialis.htm . A patent application for the ‘primary technology’ happens to be pending in the U.S. Prior to the USA Patent & Trademark Office . Yahia Gawad, MD, CEO of CardioGenics Holdings Inc. Gawad.

The Phase IIb study was a 12-week multicenter, randomized, double-blind, placebo-controlled, parallel-group study involving 79 individuals with active RA. In the scholarly study, patients treated with 1mg CF101 met all primary efficacy endpoints with statistically significant superiority over placebo in reducing signs and symptoms of RA when compared with the placebo. Can-Fite CEO Pnina Fishman mentioned, ‘We are very pleased that the Phase III style is completed and based on the positive data of the last Phase II study we believe that increasing the medication dosage will yield positive data and the ones patients with RA will be able to benefit from our oral drug.’ According to independent business info service provider visiongain, the global RA medication market is likely to generate revenues of $38.5bn in 2017.